Summary

The global alpha and beta emitters based radiopharmaceuticals market is expected to reach USD 1,769.20 million by 2032 from USD 801.45 million in 2024, growing with a substantial CAGR of 10.4% in the forecast period of 2025 to 2032.

Market Segmentation:
Global Alpha and Beta Emitters Based Radiopharmaceuticals Market, By Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Russia, Turkey, Netherlands, Poland, Norway, Austria, Ireland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Peru, Chile, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032
Overview of Global Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics:
Driver
• Increased efficacy of targeted alpha and beta therapies
• Growing adoption of theranostics in personalized medicine
• Rising clinical demand for alpha-based radiotherapies
Restraints
• Supply chain and scalability challenges from short isotope half-lives
• Stringent regulatory landscape limiting market flexibility
Opportunities
• Surge in R&D activity expanding radiopharmaceutical applications
• Expansion of Lu-177-PSMA therapy in prostate cancer treatment
Market Players:
The key players operating in the global alpha and beta emitters based radiopharmaceuticals market are:
• Novartis AG
• Eckert & Ziegler
• ITM Isotope Technologies Munich SE
• SHINE Technologies, LLC
• Actinium Pharmaceuticals, Inc.
• Alpha Tau Medical Ltd.
• ARICEUM THERAPEUTICS
• Bayer AG
• Curium
• IONETIX Corporation
• Isotopia
• Lantheus
• Lilly
• Niowave
• NMR
• Oncoinvent
• Orano Group
• Radiopharm Theranostics Limited
• Telix Pharmaceuticals Limited
• Terthera

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 36
1.1 OBJECTIVES OF THE STUDY 36
1.2 MARKET DEFINITION 36
1.3 OVERVIEW OF GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 36
1.4 MARKETS COVERED 38
2 MARKET SEGMENTATION 41
2.1 MARKETS COVERED 41
2.2 GEOGRAPHICAL SCOPE 42
2.3 YEARS CONSIDERED FOR THE STUDY 43
2.4 CURRENCY AND PRICING 43
2.5 DBMR TRIPOD DATA VALIDATION MODEL 44
2.6 MULTIVARIATE MODELLING 47
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 48
2.8 DBMR MARKET POSITION GRID 49
2.9 VENDOR SHARE ANALYSIS 50
2.10 END USER MARKET COVERAGE GRID 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 60
4.1 PORTER’S FIVE FORCES 62
4.2 PESTEL ANALYSIS 63
4.3 PIPELINE 64
4.4 SUPPLY CHAIN ECOSYSTEM 69
4.4.1 PROMINENT COMPANIES 69
4.4.2 SMALL & MEDIUM SIZE COMPANIES 69
4.4.3 END USERS 69
4.5 INDUSTRY INSIGHTS: 70
4.5.1 MICRO AND MACRO ECONOMIC FACTORS 70
4.5.2 KEY PRICING STRATEGIES 71
4.6 MARKETED DRUG ANALYSIS 72
4.6.1 DRUG 72
4.6.1.1 BRAND NAME 72
4.6.1.2 GENERIC NAME 72
 
4.6.2 THERAPEUTIC INDICATION 72
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG 72
4.6.4 DRUG PRIMARY INDICATION 72
4.6.5 MARKET STATUS 72
4.6.6 MEDICATION TYPE 73
4.6.7 DRUG DOSAGE FORM 73
4.6.8 DOSAGES AVAILABILITY 73
4.6.9 PACKAGING TYPE 73
4.6.10 DRUG ROUTE OF ADMINISTRATION 73
4.6.11 DOSING FREQUENCY 73
4.6.12 DRUG INSIGHT 73
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES 74
4.6.13.1 FORECAST MARKET OUTLOOK 74
4.6.13.2 CROSS COMPETITION 74
4.6.13.3 THERAPEUTIC PORTFOLIO 74
4.6.13.4 CURRENT DEVELOPMENT SCENARIO 74
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS 75
4.7.1 OVERVIEW 75
4.7.2 TARIFF STRUCTURES 75
4.7.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES 75
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 75
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES 75
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 75
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 76
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 76
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 76
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 76
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 76
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 76
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 76
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 76
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 77
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 77
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 77
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 77
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 77
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 77
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 77
4.9 EPIDEMIOLOGY OVERVIEW 78
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER 78
4.9.2 TREATMENT RATE 79
4.9.3 MORTALITY RATE 79
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 80
4.9.5 PATIENT TREATMENT SUCCESS RATES 80
5 REGULATORY FRAMEWORK 82
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 82
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 82
5.1.2 REGULATORY APPROVAL PATHWAYS 83
5.1.3 LICENSING AND REGISTRATION 83
5.1.4 POST-MARKETING SURVEILLANCE 83
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 83
5.2 REGULATORY FRAMEWORK OVERVIEW FOR THE SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 84
5.2.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 84
5.2.2 REGULATORY APPROVAL PATHWAYS 84
5.2.3 LICENSING AND REGISTRATION 84
5.2.4 POST-MARKETING SURVEILLANCE 84
5.2.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 85
5.3 REGULATORY FRAMEWORK OVERVIEW FOR THE EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 85
5.3.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 85
5.3.2 REGULATORY APPROVAL PATHWAYS 85
5.3.3 LICENSING AND REGISTRATION 86
5.3.4 POST-MARKETING SURVEILLANCE 86
5.3.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 86
5.4 REGULATORY FRAMEWORK OVERVIEW FOR THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 86
5.4.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 86
5.4.2 REGULATORY APPROVAL PATHWAYS 87
5.4.3 LICENSING AND REGISTRATION 87
5.4.4 POST-MARKETING SURVEILLANCE 88
5.4.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 88
5.5 REGULATORY FRAMEWORK OVERVIEW FOR THE MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 88
5.5.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 88
5.5.2 REGULATORY APPROVAL PATHWAYS 88
5.5.3 LICENSING AND REGISTRATION 89
5.5.4 POST-MARKETING SURVEILLANCE 89
5.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 89
6 MARKET OVERVIEW 90
6.1 DRIVERS 92
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES 92
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE 92
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES 93
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND 94
6.2 RESTRAINTS 95
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES 95
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY 95
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE 96
6.3 OPPORTUNITIES 97
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS 97
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT 98
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION 98
6.4 CHALLENGES 99
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 99
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY 100
7 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 102
7.1 OVERVIEW 103
7.2 BETA EMITTERS 106
7.2.1 LUTETIUM-177 106
7.2.2 TERBIUM-161 106
7.3 ALPHA EMITTERS 107
7.3.1 ACTINIUM-225 107
7.3.2 LEAD -212 107
8 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES 108
8.1 OVERVIEW 109
8.2 REACTOR-PRODUCED ISOTOPES 112
8.3 GENERATOR-PRODUCED ISOTOPES 112
8.4 OTHERS 113
 
9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION 114
9.1 OVERVIEW 115
9.2 ONCOLOGY 118
9.2.1 PROSTATE CANCER 119
9.2.2 NEUROENDOCRINE TUMORS 119
9.2.3 LIVER CANCER 119
9.2.4 BRAIN TUMORS 119
9.2.5 BREAST CANCER 119
9.2.6 LEUKEMIA 119
9.3 OTHERS 119
10 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE 120
10.1 OVERVIEW 121
10.2 SMALL MOLECULE LIGANDS 124
10.3 PEPTIDES 124
10.4 MONOCLONAL ANTIBODIES 125
10.5 OTHERS 125
11 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER 126
11.1 OVERVIEW 127
11.2 HOSPITALS 130
11.2.1 ONCOLOGY CENTERS 130
11.2.2 NUCLEAR MEDICINE DEPARTMENTS 130
11.3 RADIOPHARMACIES 131
11.4 RESEARCH INSTITUTES 131
12 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION 132
12.1 OVERVIEW 133
12.2 NORTH AMERICA 136
12.2.1 U.S. 140
12.2.2 CANADA 143
12.2.3 MEXICO 146
 
12.3 EUROPE 149
12.3.1 GERMANY 153
12.3.2 U.K. 156
12.3.3 FRANCE 159
12.3.4 ITALY 162
12.3.5 SPAIN 165
12.3.6 POLAND 168
12.3.7 RUSSIA 171
12.3.8 NORWAY 174
12.3.9 TURKEY 177
12.3.10 AUSTRIA 180
12.3.11 IRELAND 183
12.3.12 NETHERLANDS 186
12.3.13 SWITZERLAND 189
12.3.14 REST OF EUROPE 192
12.4 ASIA PACIFIC 193
12.4.1 CHINA 198
12.4.2 AUSTRALIA 201
12.4.3 JAPAN 204
12.4.4 SOUTH KOREA 207
12.4.5 SINGAPORE 210
12.4.6 INDIA 213
12.4.7 INDONESIA 216
12.4.8 PHILIPPINES 219
12.4.9 THAILAND 222
12.4.10 MALAYSIA 225
12.4.11 VIETNAM 228
12.4.12 TAIWAN 231
12.4.13 REST OF ASIA-PACIFIC 234
12.5 SOUTH AMERICA 235
12.5.1 BRAZIL 239
12.5.2 ARGENTINA 242
12.5.3 CHILE 245
12.5.4 PERU 248
12.5.5 REST OF SOUTH AMERICA 251
 
12.6 MIDDLE EAST AND AFRICA 252
12.6.1 SOUTH AFRICA 256
12.6.2 EGYPT 259
12.6.3 SAUDI ARABIA 262
12.6.4 U.A.E. 265
12.6.5 KUWAIT 268
12.6.6 ISRAEL 271
12.6.7 REST OF MIDDLE EAST AND AFRICA 274
13 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 275
13.1 COMPANY SHARE ANALYSIS: GLOBAL 275
13.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 276
13.3 COMPANY SHARE ANALYSIS: EUROPE 277
13.4 COMPANY SHARE ANALYSIS: NORTH AMERICA 278
14 SWOT ANALYSIS 279
15 COMPANY PROFILES 280
15.1 NOVARTIS AG 280
15.1.1 COMPANY SNAPSHOT 280
15.1.2 REVENUE ANALYSIS 281
15.1.3 COMPANY SHARE ANALYSIS 281
15.1.4 PRODUCT PORTFOLIO 282
15.1.5 RECENT DEVELOPMENTS 282
15.2 ECKERT & ZIEGLER 283
15.2.1 COMPANY SNAPSHOT 283
15.2.2 REVENUE ANALYSIS 283
15.2.3 COMPANY SHARE ANALYSIS 284
15.2.4 PRODUCT PORTFOLIO 284
15.2.5 RECENT DEVELOPMENTS 285
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE 286
15.3.1 COMPANY SNAPSHOT 286
15.3.2 COMPANY SHARE ANALYSIS 286
15.3.3 PRODUCT PORTFOLIO 287
15.3.4 RECENT DEVELOPMENT 287
15.4 SHINE TECHNOLOGIES, LLC 288
15.4.1 COMPANY SNAPSHOT 288
15.4.2 COMPANY SHARE ANALYSIS 288
15.4.3 PRODUCT PORTFOLIO 289
15.4.4 RECENT DEVELOPMENT 289
15.5 ACTINIUM PHARMACEUTICALS, INC. 290
15.5.1 COMPANY SNAPSHOT 290
15.5.2 PIPELINE PRODUCT PORTFOLIO 290
15.5.3 RECENT DEVELOPMENTS 291
15.6 ALPHA TAU MEDICAL LTD. 292
15.6.1 COMPANY SNAPSHOT 292
15.6.2 PIPELINE PRODUCT PORTFOLIO 292
15.6.3 RECENT DEVELOPMENT 292
15.7 ARICEUM THERAPEUTICS 293
15.7.1 COMPANY SNAPSHOT 293
15.7.2 PIPELINE PRODUCT PORTFOLIO 293
15.7.3 RECENT DEVELOPMENT 293
15.8 BAYER AG 294
15.8.1 COMPANY SNAPSHOT 294
15.8.2 REVENUE ANALYSIS 294
15.8.3 PIPELINE PRODUCT PORTFOLIO 295
15.8.4 RECENT DEVELOPMENT 295
15.9 CURIUM 296
15.9.1 COMPANY SNAPSHOT 296
15.9.2 PIPELINE PRODUCT PORTFOLIO 296
15.9.3 RECENT DEVELOPMENT 296
15.10 IONETIX CORPORATION 297
15.10.1 COMPANY SNAPSHOT 297
15.10.2 PIPELINE PRODUCT PORTFOLIO 297
15.10.3 RECENT DEVELOPMENT 297
15.11 ISOTOPIA 298
15.11.1 COMPANY SNAPSHOT 298
15.11.2 PIPELINE PRODUCT PORTFOLIO 298
15.11.3 RECENT DEVELOPMENT 298
15.12 LANTHEUS 299
15.12.1 COMPANY SNAPSHOT 299
15.12.2 REVENUE ANALYSIS 299
15.12.3 PIPELINE PRODUCT PORTFOLIO 300
15.12.4 RECENT DEVELOPMENT 301
15.13 LILLY 302
15.13.1 COMPANY SNAPSHOT 302
15.13.2 REVENUE ANALYSIS 302
15.13.3 PIPELINE PRODUCT PORTFOLIO 303
 
15.14 NIOWAVE 304
15.14.1 COMPANY SNAPSHOT 304
15.14.2 PIPELINE PRODUCT PORTFOLIO 304
15.14.3 RECENT DEVELOPMENT 304
15.15 NMR 305
15.15.1 COMPANY SNAPSHOT 305
15.15.2 PIPELINE PRODUCT PORTFOLIO 305
15.15.3 RECENT DEVELOPMENT 305
15.16 ONCOINVENT 306
15.16.1 COMPANY SNAPSHOT 306
15.16.2 PIPELINE PRODUCT PORTFOLIO 306
15.16.3 RECENT DEVELOPMENT 306
15.17 ORANO GROUP 307
15.17.1 COMPANY SNAPSHOT 307
15.17.2 REVENUE ANALYSIS 307
15.17.3 PIPELINE PRODUCT PORTFOLIO 308
15.17.4 RECENT DEVELOPMENT 309
15.18 RADIOPHARM THERANOSTICS LIMITED 310
15.18.1 COMPANY SNAPSHOT 310
15.18.2 PIPELINE PRODUCT PORTFOLIO 310
15.18.3 RECENT DEVELOPMENT 311
15.19 TELIX PHARMACEUTICALS LIMITED 312
15.19.1 COMPANY SNAPSHOT 312
15.19.2 REVENUE ANALYSIS 312
15.19.3 PIPELINE PRODUCT PORTFOLIO 313
15.19.4 RECENT DEVELOPMENT 314
15.20 TERTHERA 315
15.20.1 COMPANY SNAPSHOT 315
15.20.2 PIPELINE PRODUCT PORTFOLIO 315
15.20.3 RECENT DEVELOPMENT 315
15.20.4 RECENT DEVELOPMENT 315
16 QUESTIONNAIRE 316
17 RELATED REPORTS 319